About Eli Lilly and Co (LLY)
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Company's Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, such as Humalog and Humalog Mix 75/25; neuroscience products, such as Cymbalta and Zyprexa; oncology products, such as Alimta and Cyramza, and cardiovascular products, such as Cialis and ReoPro. The Company's animal health products segment includes products for food animals, such as Rumensin and Posilac; products for companion animals, such as Onsior and Osurnia, and Novartis Animal Health (Novartis AH) products.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Major
- Sub-Industry: Pharmaceuticals
- Exchange: NYSE
- Symbol: LLY
- CUSIP: 53245710
- Previous Close: $84.36
- 50 Day Moving Average: $81.21
- 200 Day Moving Average: $77.16
- 52-Week Range: $1,050,875,000.00 - $64.18
- Trailing P/E Ratio: 32.70
- Foreward P/E Ratio: 19.26
- P/E Growth: 1.66
- Market Cap: $88.65B
- Outstanding Shares: 1,050,875,000
- Beta: 0.3
- Net Margins: 12.90%
- Return on Equity: 24.74%
- Return on Assets: 10.30%
- Debt-to-Equity Ratio: 0.56%
- Current Ratio: 1.62%
- Quick Ratio: 1.15%
Companies Related to Eli Lilly and Co:
Earnings History for Eli Lilly and Co (NYSE:LLY)Earnings History by Quarter for Eli Lilly and Co (NYSE:LLY)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/25/2017|| || || || || || || || |
|1/31/2017||Q416||$0.98||$0.95||$5.54 billion||$5.76 billion||View||N/A|
|10/25/2016||Q316||$0.96||$0.88||$4.23 billion||$5.19 billion||View||Listen|
|7/26/2016||Q216||$0.86||$0.86||$5.14 billion||$5.40 billion||View||Listen|
|4/26/2016||Q116||$0.85||$0.83||$4.82 billion||$4.87 billion||View||Listen|
|1/28/2016||Q415||$0.78||$0.78||$5.33 billion||$5.38 billion||View||Listen|
|10/22/2015||Q315||$0.76||$0.89||$4.99 billion||$4.96 billion||View||Listen|
|7/23/2015||Q215||$0.74||$0.90||$4.89 billion||$4.98 billion||View||Listen|
|4/23/2015||Q115||$0.76||$0.87||$4.62 billion||$4.64 billion||View||N/A|
|1/30/2015||Q414||$0.74||$0.75||$5.21 billion||$5.12 billion||View||N/A|
|10/23/2014||Q314||$0.67||$0.66||$4.83 billion||$4.88 billion||View||Listen|
|7/24/2014||Q214||$0.65||$0.68||$4.88 billion||$4.94 billion||View||N/A|
|4/24/2014||Q114||$0.70||$0.70||$4.78 billion||$4.68 billion||View||N/A|
|1/30/2014||Q413||$0.72||$0.74||$5.46 billion||$5.81 billion||View||Listen|
|10/23/2013||Q313||$1.04||$1.11||$5.76 billion||$5.77 billion||View||N/A|
|7/24/2013||Q2 2013||$1.01||$1.16||$5.82 billion||$5.93 billion||View||N/A|
|4/24/2013||Q1 2013||$1.05||$1.14||$5.66 billion||$5.60 billion||View||N/A|
|1/29/2013||Q4 2012||$0.82||$0.85||$5.78 billion||$5.96 billion||View||N/A|
Earnings Estimates for Eli Lilly and Co (NYSE:LLY)
Current Year EPS Consensus Estimate: $4.10 EPS
Next Year EPS Consensus Estimate: $4.38 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Current Dividend Information for Eli Lilly and Co (NYSE:LLY)
|Most Recent Dividend:||3/10/2017|
|Dividend Growth:||1.30% (3 Year Average)|
|Payout Ratio:||80.62% (Trailing 12 Months of Earnings) |
50.73% (Based on This Year's Estimates)
47.49% (Based on Next Year's Estimates)
|Track Record:||2 Years of Consecutive Dividend Growth|
Dividend History by Quarter for Eli Lilly and Co (NYSE:LLY)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Eli Lilly and Co (NYSE:LLY)
Insider Ownership Percentage: 0.20%Insider Trades by Quarter for Eli Lilly and Co (NYSE:LLY)
Institutional Ownership Percentage: 75.15%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/17/2017||Lilly Endowment Inc||Major Shareholder||Sell||230,000||$80.27||$18,462,100.00|| |
|2/6/2017||Alfonso G Zulueta||SVP||Sell||15,000||$77.66||$1,164,900.00|| |
|2/3/2017||Derica W Rice||EVP||Sell||11,162||$77.14||$861,036.68|| |
|2/2/2017||Donald A Zakrowski||Insider||Sell||2,000||$77.52||$155,040.00|| |
|2/1/2017||Lilly Endowment Inc||Major Shareholder||Sell||220,000||$77.35||$17,017,000.00|| |
|12/16/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$72.59||$14,518,000.00|| |
|12/16/2016||Melissa S Barnes||Insider||Sell||2,093||$82.23||$172,107.39|| |
|12/16/2016||R David Hoover||Director||Buy||500||$71.85||$35,925.00|| |
|12/16/2016||Susan Mahony||SVP||Sell||20,242||$72.65||$1,470,581.30|| |
|10/5/2016||Maria A Crowe||Insider||Sell||2,248||$81.37||$182,919.76|| |
|8/15/2016||Jackson P Tai||Director||Buy||5,773||$80.43||$464,322.39|| |
|8/12/2016||Jackson P Tai||Director||Buy||2,560||$80.42||$205,875.20|| |
|7/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||205,000||$82.94||$17,002,700.00|| |
|7/28/2016||Donald A Zakrowski||Insider||Sell||1,213||$83.16||$100,873.08|| |
|7/28/2016||Lilly Endowment Inc||Major Shareholder||Sell||240,000||$82.87||$19,888,800.00|| |
|7/12/2016||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$79.54||$16,703,400.00|| |
|7/7/2016||Lilly Endowment Inc||Major Shareholder||Sell||225,000||$79.14||$17,806,500.00|| |
|6/30/2016||Lilly Endowment Inc||Major Shareholder||Sell||215,000||$78.46||$16,868,900.00|| |
|6/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||220,000||$77.86||$17,129,200.00|| |
|6/10/2016||Melissa S Barnes||SVP||Sell||992||$73.77||$73,179.84|| |
|5/31/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$75.12||$15,024,000.00|| |
|5/12/2016||Jackson P Tai||Director||Buy||1,080||$75.75||$81,810.00|| |
|5/12/2016||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$75.86||$14,413,400.00|| |
|5/2/2016||Donald A Zakrowski||CAO||Sell||1,600||$75.86||$121,376.00|| |
|4/29/2016||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$75.44||$13,579,200.00|| |
|4/27/2016||Alfonso G Zulueta||SVP||Sell||12,000||$76.27||$915,240.00|| |
|4/8/2016||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$74.29||$14,858,000.00|| |
|2/5/2016||Stephen F Fry||SVP||Sell||15,230||$78.87||$1,201,190.10|| |
|2/3/2016||David A. Ricks||SVP||Sell||5,733||$77.66||$445,224.78|| |
|2/3/2016||Derica W. Rice||CFO||Sell||10,483||$77.78||$815,367.74|| |
|2/1/2016||Jackson P Tai||Director||Buy||3,170||$78.62||$249,225.40|| |
|1/29/2016||Alfonso G Zulueta||SVP||Sell||5,000||$78.75||$393,750.00|| |
|12/21/2015||Lilly Endowment Inc||Major Shareholder||Sell||205,000||$86.00||$17,630,000.00|| |
|12/15/2015||Lilly Endowment Inc||Major Shareholder||Sell||215,000||$85.60||$18,404,000.00|| |
|12/9/2015||Enrique A Conterno||VP||Sell||25,000||$83.88||$2,097,000.00|| |
|12/2/2015||Lilly Endowment Inc||major shareholder||Sell||210,000||$85.09||$17,868,900.00|| |
|11/20/2015||Lilly Endowment Inc||major shareholder||Sell||205,000||$84.54||$17,330,700.00|| |
|10/29/2015||Lilly Endowment Inc||major shareholder||Sell||200,000||$82.28||$16,456,000.00|| |
|10/9/2015||Lilly Endowment Inc||major shareholder||Sell||215,000||$85.86||$18,459,900.00|| |
|10/5/2015||Lilly Endowment Inc||major shareholder||Sell||260,000||$86.46||$22,479,600.00|| |
|9/18/2015||Lilly Endowment Inc||major shareholder||Sell||250,000||$89.04||$22,260,000.00|| |
|6/10/2015||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$82.39||$17,301,900.00|| |
|6/4/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$77.90||$15,580,000.00|| |
|5/29/2015||Jeffrey N Simmons||SVP||Sell||20,000||$78.08||$1,561,600.00|| |
|5/20/2015||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$73.43||$13,951,700.00|| |
|5/15/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$72.83||$14,566,000.00|| |
|5/8/2015||Lilly Endowment Inc||Major Shareholder||Sell||195,000||$73.28||$14,289,600.00|| |
|5/1/2015||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$73.09||$14,618,000.00|| |
|3/30/2015||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$73.94||$13,309,200.00|| |
|3/23/2015||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$76.97||$14,624,300.00|| |
|3/9/2015||Stephen F Fry||SVP||Sell||4,000||$69.27||$277,080.00|| |
|2/4/2015||David A Ricks||SVP||Sell||3,147||$69.99||$220,258.53|| |
|2/4/2015||Derica W Rice||CFO||Sell||5,316||$70.00||$372,120.00|| |
|2/4/2015||Jan M Lundberg||EVP||Sell||11,085||$70.08||$776,836.80|| |
|2/3/2015||Jan M Lundberg||EVP||Sell||121,711||$70.78||$8,614,704.58|| |
|2/2/2015||David A Ricks||SVP||Sell||4,769||$71.51||$341,031.19|| |
|2/2/2015||Derica W Rice||CFO||Sell||10,068||$71.84||$723,285.12|| |
|12/4/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$71.92||$13,664,800.00|| |
|12/2/2014||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$70.14||$12,625,200.00|| |
|11/13/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$67.73||$13,546,000.00|| |
|11/5/2014||Lilly Endowment Inc||Major Shareholder||Sell||180,000||$67.00||$12,060,000.00|| |
|11/4/2014||Fionnuala M Walsh||SVP||Sell||15,000||$67.00||$1,005,000.00|| |
|11/3/2014||Enrique A Conterno||VP||Sell||5,000||$66.03||$330,150.00|| |
|10/31/2014||Fionnuala M Walsh||SVP||Sell||7,376||$66.58||$491,094.08|| |
|10/31/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$66.40||$12,616,000.00|| |
|10/30/2014||Lilly Endowment Inc||Major Shareholder||Sell||175,000||$66.58||$11,651,500.00|| |
|10/24/2014||Maria A Crowe||Insider||Sell||2,750||$65.77||$180,867.50|| |
|10/6/2014||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$65.63||$13,782,300.00|| |
|10/1/2014||Enrique A Conterno||VP||Sell||5,000||$64.86||$324,300.00|| |
|9/30/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$65.07||$13,014,000.00|| |
|9/10/2014||Lilly Endowment Inc||Major Shareholder||Sell||210,000||$64.77||$13,601,700.00|| |
|9/3/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$63.99||$12,798,000.00|| |
|9/2/2014||Enrique A Conterno||VP||Sell||5,000||$63.60||$318,000.00|| |
|7/29/2014||Lilly Endowment Inc||Major Shareholder||Sell||250,000||$63.03||$15,757,500.00|| |
|7/28/2014||Susan Mahony||SVP||Sell||2,065||$63.30||$130,714.50|| |
|7/25/2014||Enrique A Conterno||VP||Sell||10,000||$63.79||$637,900.00|| |
|7/25/2014||Susan Mahony||SVP||Sell||30,000||$63.90||$1,917,000.00|| |
|7/1/2014||Lilly Endowment Inc||Major Shareholder||Sell||235,000||$62.30||$14,640,500.00|| |
|6/25/2014||Lilly Endowment Inc||Major Shareholder||Sell||245,000||$62.68||$15,356,600.00|| |
|6/20/2014||Lilly Endowment Inc||Major Shareholder||Sell||230,000||$61.55||$14,156,500.00|| |
|6/16/2014||Lilly Endowment Inc||Major Shareholder||Sell||200,000||$58.73||$11,746,000.00|| |
|6/5/2014||Lilly Endowment Inc||Major Shareholder||Sell||190,000||$59.53||$11,310,700.00|| |
|5/21/2014||Lilly Endowment Inc||major shareholder||Sell||230,000||$58.90||$13,547,000.00|| |
|5/12/2014||Jackson Tai||Director||Buy||17,157||$59.19||$1,015,522.83|| |
|5/12/2014||Lilly Endowment Inc||major shareholder||Sell||210,000||$59.33||$12,459,300.00|| |
|5/6/2014||Lilly Endowment Inc||major shareholder||Sell||190,000||$58.79||$11,170,100.00|| |
|4/29/2014||Lilly Endowment Inc||major shareholder||Sell||200,000||$59.43||$11,886,000.00|| |
|4/28/2014||Lilly Endowment Inc||major shareholder||Sell||150,000||$58.64||$8,796,000.00|| |
|8/15/2013||Enrique Conterno||VP||Sell||5,000||$53.79||$268,950.00|| |
|7/29/2013||Jacques Tapiero||SVP||Sell||7,500||$53.74||$403,050.00|| |
|7/15/2013||Enrique A Conterno||VP||Sell||5,000||$51.43||$257,150.00|| |
|6/17/2013||Enrique A Conterno||VP||Sell||5,000||$52.45||$262,250.00|| |
|5/15/2013||Enrique A Conterno||VP||Sell||5,000||$56.15||$280,750.00|| |
|5/10/2013||Jeffrey N Simmons||SVP||Sell||10,000||$54.49||$544,900.00|| |
|3/26/2013||Susan Mahony||SVP||Sell||5,000||$56.00||$280,000.00|| |
Headline Trends for Eli Lilly and Co (NYSE:LLY)
Latest Headlines for Eli Lilly and Co (NYSE:LLY)
Frequently Asked Questions for Eli Lilly and Co (NYSE:LLY)
What is Eli Lilly and Co's stock symbol?
Eli Lilly and Co trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How often does Eli Lilly and Co pay dividends? What is the dividend yield for Eli Lilly and Co?
Eli Lilly and Co declared a quarterly dividend on Tuesday, December 13th. Stockholders of record on Wednesday, February 15th will be paid a dividend of $0.52 per share on Friday, March 10th. This represents a $2.08 annualized dividend and a dividend yield of 2.47%. The ex-dividend date of this dividend is Monday, February 13th. This is an increase from Eli Lilly and Co's previous quarterly dividend of $0.51.
How were Eli Lilly and Co's earnings last quarter?
Eli Lilly and Co (NYSE:LLY) announced its quarterly earnings results on Tuesday, January, 31st. The company reported $0.95 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.98 by $0.03. The business earned $5.76 billion during the quarter, compared to analyst estimates of $5.54 billion. Eli Lilly and Co had a net margin of 12.90% and a return on equity of 24.74%. The business's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.78 earnings per share.
When will Eli Lilly and Co make its next earnings announcement?
Eli Lilly and Co is scheduled to release their next quarterly earnings announcement on Tuesday, April, 25th 2017.
What guidance has Eli Lilly and Co issued on next quarter's earnings?
Eli Lilly and Co issued an update on its FY17 earnings guidance on Tuesday, January, 31st. The company provided earnings per share guidance of $4.05-4.15 for the period, compared to the Thomson Reuters consensus estimate of $4.09. The company issued revenue guidance of $21.8-22.3 billion, compared to the consensus revenue estimate of $21.98 billion.
Where is Eli Lilly and Co's stock going? Where will Eli Lilly and Co's stock price be in 2017?
15 equities research analysts have issued 1 year price targets for Eli Lilly and Co's shares. Their predictions range from $73.00 to $100.00. On average, they expect Eli Lilly and Co's stock price to reach $87.82 in the next year.
What are analysts saying about Eli Lilly and Co stock?
Here are some recent quotes from research analysts about Eli Lilly and Co stock:
- 1. According to Zacks Investment Research, "Lilly’s fourth-quarter results were mixed with earnings missing estimates but revenues beating the same. Earnings jumped 22% year over year backed by strong diabetes sales. In 2017, while new products like Trulicity, Taltz, Basaglar, Cyramza, Jardiance and Lartruvo are expected to see higher revenues, Lilly expects some established products like Trajenta, Forteo and Humalog to continue doing well. Lilly expects to launch 20 new products between 2014 and 2023, including the launch of at least two new indications/line extensions on an average every year. Although the stock’s decline was sharper than the large cap pharma industry in 2016, it has done well in 2017. However, Alimta will continue to be impacted by competition. Other headwinds include competition from immuno-oncology agents as well as loss of exclusivity for many drugs in the emerging markets." (2/15/2017)
- 2. JPMorgan Chase & Co. analysts commented, "While the FDA recommends both cognitive and function endpoints for Alzheimer's drug approvals, we would not be surprised to see a positive cognitive endpoint and a trend towards functional benefit ultimately being sufficient for approval," analyst Chris Schott wrote in a note.Outcomes And ProbabilitiesThe analyst sees more than 15 percent upside in the stock if EXP-3 study meets both primary and secondary endpoints, which he states are between a 10–20 percent probability.The analyst expects a more muted 10 percent upside if the study hits on its primary but only shows a trend on secondary endpoints (50–60 percent probability).Further, Schott predicts a 10 percent drop in stock if the study fails both endpoints (about 30 percent probability).Moreover, irrespective of the outcome of solanezumab, Schott sees a diverse range of new product opportunities supporting Eli Lilly's greater than 5 percent top-line growth target. Related Link: Apple, Eli Lilly, U.S. Steel: Fast Money Picks For September 7The analyst forecast about 6 percent top-line growth through 2020, with about 5 percent excluding risk adjusted solanezumab sales.The analyst's sales growth target is also supported by a number of $1+ billion product opportunities such as Trulicity, Jardiance, Taltz, baricitinib and abemaciclib."In aggregate, we forecast recent/upcoming new product launches to generate $11.4 billion in sales by 2020," (9/8/2016)
Who owns Eli Lilly and Co stock?
Eli Lilly and Co's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (3.89%), Franklin Resources Inc. (3.24%), Norges Bank (0.85%), Janus Capital Management LLC (0.79%), Putnam Investments LLC (0.38%) and Asset Management One Co. Ltd. (0.16%). Company insiders that own Eli Lilly and Co stock include Alfonso G Zulueta, David A Ricks, Derica W Rice, Donald A Zakrowski, Enrique A Conterno, Jackson P Tai, Jeffrey N Simmons, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes, R David Hoover, Stephen F Fry and Susan Mahony.
Who sold Eli Lilly and Co stock? Who is selling Eli Lilly and Co stock?
Eli Lilly and Co's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Putnam Investments LLC, Capital Guardian Trust Co., Janus Capital Management LLC, I.G. Investment Management LTD., Cadinha & Co. LLC and Gabelli Funds LLC. Company insiders that have sold Eli Lilly and Co stock in the last year include Alfonso G Zulueta, Derica W Rice, Donald A Zakrowski, Lilly Endowment Inc, Maria A Crowe, Melissa S Barnes and Susan Mahony.
Who bought Eli Lilly and Co stock? Who is buying Eli Lilly and Co stock?
Eli Lilly and Co's stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Franklin Resources Inc., State Street Corp, Asset Management One Co. Ltd., Alyeska Investment Group L.P., Russell Investments Group Ltd., DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main and Renaissance Technologies LLC. Company insiders that have bought Eli Lilly and Co stock in the last two years include Jackson P Tai and R David Hoover.
How do I buy Eli Lilly and Co stock?
Shares of Eli Lilly and Co can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Eli Lilly and Co stock cost?
One share of Eli Lilly and Co stock can currently be purchased for approximately $84.36.
Eli Lilly and Co (LLY) Chart for Wednesday, March, 22, 2017